SIRPA and neoplasm: It is worth noting that SIRPα-exosomes can shorten the time required for exosomes to reach the tumor target of CD47 overexpression, and only low-dose SIRPα-exosomes can effectively inhibit the growth of tumor in vivo by blocking CD47-SIRPα, so as to improve the therapeutic effect [129].